Yahoo
NasdaqGS - Nasdaq Real Time Price USD

IDEXX Laboratories, Inc. (IDXX)

676.04 +5.33 (+0.79%)
At close: November 6 at 4:00:01 PM EST
681.44 +5.40 (+0.80%)
Overnight: 3:34:12 AM EST
Trade IDXX on Coinbase
Chart Range Bar
Loading chart for IDXX

What's happening with IDXX?

10m ago
Powered by Yahoo Scout

IDEXX Laboratories delivered a strong third quarter, beating estimates and raising its 2026 revenue and earnings outlook. Growth remained concentrated in recurring companion-animal diagnostics, while softer U.S. clinic visits, margin pressure, and a premium valuation remain key investor watchpoints.

Powered by Yahoo Scout
  • Previous Close 670.71
  • Open 652.12
  • Bid 668.97 x 100
  • Ask 645.63 x 100
  • Day's Range 650.00 - 680.57
  • 52 Week Range 500.61 - 769.98
  • Volume 589,072
  • Avg. Volume 569,959
  • Market Cap (intraday) 53.263B
  • Beta (5Y Monthly) 1.54
  • PE Ratio (TTM) 45.56
  • EPS (TTM) 14.84
  • Earnings Date (est.) Feb 1, 2027
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 717.17
  • Morningstar Rating Rating available with Stock Picks access

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

www.idexx.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IDXX
0.07%
S&P 500 (^GSPC)
7.76%

1-Year Return

IDXX
5.28%
S&P 500 (^GSPC)
9.77%

3-Year Return

IDXX
59.81%
S&P 500 (^GSPC)
68.96%

5-Year Return

IDXX
6.06%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.21B
Earnings 317.14M
Profit Margin 26.12%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
200M
400M
600M
800M
1B
1B
23.0%
24.0%
25.0%
26.0%
27.0%

Analyst Insights

View More

Analyst Price Targets

470.00 Low
717.17 Average
676.04 Current
810.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/3/2026
Analyst Morgan Stanley
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 805 -> 810

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.36%

  • Return on Assets (ttm)

    26.70%

  • Return on Equity (ttm)

    68.93%

  • Revenue (ttm)

    4.66B

  • Net Income Avi to Common (ttm)

    1.18B

  • Diluted EPS (ttm)

    14.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    197.54M

  • Total Debt/Equity (mrq)

    52.05%

  • Levered Free Cash Flow (ttm)

    1.06B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: